FDA Clears Dual-Head SPECT/CT System with Deep Learning Image Reconstruction
The combination of the Aurora SPECT/CT system with AI-enabled Clarify DL image reconstruction reportedly offers the potential of enhanced image quality and streamlined workflows in nuclear medicine.
The Food and Drug Administration (FDA) has granted 510(k) clearance for the Aurora single photon emission computed tomography/computed tomography (SPECT/CT) system and Clarify DL deep learning image reconstruction.
GE HealthCare, the developer of the dual-head Aurora SPECT/CT system, said the device offers the following key benefits:
The newly FDA-cleared dual-head Aurora SPECT/CT system has a 40 mm detector, which offers twice the coverage of CTs from other hybrid systems, and 128-slice capabilities across imaging applications in neurology, cardiology, and oncology, according to GE HealthCare, the developer of the Aurora SPECT/CT platform. (Image courtesy of GE HealthCare.)
• a 40 mm detector offering twice the coverage of CTs from other hybrid systems;
• 128-slice capabilities across imaging applications in neurology, cardiology, and oncology; and
• a 5/8-inch crystal Nal detector, which allows use of a variety of radiopharmaceuticals including theranostics.
Through advanced deep learning technology, GE HealthCare maintained that Clarity DL image reconstruction bolsters quality for bone SPECT imaging without the need for increased radiation dosing or scan time.
“Aurora’s seamless integration of SPECT and CT components will allow us to perform comprehensive, high-quality diagnostic exams in a single session, while its support of Clarify DL deep-learning image reconstruction enables enhanced image quality performance,” noted Donna Plecha, M.D., chair of the Department of Radiology at University Hospitals Cleveland Medical Center, and a professor of radiology at the Case Western Reserve University School of Medicine in Cleveland.
Recent Videos
Related Content
Mammography Study Compares False Positives Between AI and Radiologists in DBT Screening
May 8th 2025Article
For DBT breast cancer screening, 47 percent of radiologist-only flagged false positives involved mass presentations whereas 40 percent of AI-only flagged false positive cases involved benign calcifications, according to research presented at the recent American Roentgen Ray Society (ARRS) conference.
Study Shows No Impact of Hormone Therapy on PET/CT with 18F-Piflufolastat in PCa Imaging
May 7th 2025Article
For patients with recurrent or metastatic prostate cancer, new research findings showed no significant difference in the sensitivity of 18F-piflufolastat PET/CT between patients on concurrent hormone therapy and those without hormone therapy.
